GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 w
Buoyed by data from a trial of its T-cell engager (TCE) therapy in prostate cancer that almost tripled its share price, Janux Therapeutics has moved quickly to file a stoc
Iovance Biotherapeutics has carved out a piece of biotech history, becoming the first company to win FDA clearance for a cell therapy used to treat a solid tumour.
Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug
Astellas has signed an R&D and licensing deal with Kelonia Therapeutics that aims to develop CAR-T therapies for cancer that will push the boundaries of what can be ac
Germany’s BioNTech has taken a $200 million stake in Autolus in a private placement that will allow it to tap into the UK company’s manufacturing capacity for CAR-T therap
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.